Source: Υπουργείο Υγείας (CY) Revision Year: 2023 Publisher: Sanofi Winthrop Industrie, 82 avenue Raspail, 94250 Gentilly, France
Depakine Chrono 500 mg, prolonged-release tablets.
| Pharmaceutical Form |
|---|
|
Prolonged-release tablets. |
Sodium valproate 333 mg
Valproic acid 145 mg
Quantity corresponding to 500 mg sodium valproate per tablet.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Valproic acid |
Valproic acid is anti-convulsant. The most likely mode of action for valproate is potentiation of the inhibitory action of gamma amino butyric acid (GABA) through an action on the further synthesis or further metabolism of GABA. |
| List of Excipients |
|---|
|
Ethylcellulose 20 |
Bottle of 30 prolonged-release tablets.
Sanofi Winthrop Industrie, 82 avenue Raspail, 94250 Gentilly, France
19172
Date of first authorisation: 23 February 2001
Date of latest renewal: 5 January 2012
| Drug | Countries | |
|---|---|---|
| DEPAKINE-CHRONO | Austria, Cyprus, Estonia, Spain, France, Croatia, Lithuania, Poland, Romania, Tunisia |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
